AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04879862 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epidural stimulation + Stand Training
Description: Participants may use a standing apparatus or a less assistive device such as walker or cane. In case of upper limbs and trunk control insufficient for safely using the standing apparatus, participants will be placed on the treadmill, and a body weight support system. In this case, the level of body weight support will be continuously reduced as the individuals increase their ability to bear weight. A trainer positioned behind the participant will aid in pelvis and trunk stabilization. Trainer(s) positioned at the lower limb will provide manual facilitation for knee extension during standing. Manual facilitation at the trunk-pelvis and at the legs will be used only when needed.Participants will be encouraged to stand for as long as possible throughout the training session, with the goal to stand for 60 minutes with the least amount of assistance.
Study NCT04879862 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epidural stimulation + Step Training
Description: Participants may be placed on the treadmill in an upright position and suspended in a harness. All trainers are careful to provide manual assistance only when needed. A trainer positioned behind the research participant will aid in pelvis and trunk stabilization, as well as appropriate weight shifting and hip rotation during the step cycle. Trainers positioned at each limb will provide manual assistance to promote knee extension and knee flexion and toe clearance. Research participants will step at various body weight load and speed. Research participants will take a break and rest at any time they feel the need to during the session. If independence is achieved during stepping, some training might be performed overground with appropriate assistive device and manual assistance to maintain participant safety. Participants will be encouraged to step for 60 minutes with the least amount of assistance. Seated or standing resting periods will occur when requested by the individuals
Study NCT04879862 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epidural stimulation + Bladder Capacity Training
Description: We will initially conduct daily training for capacity in a supervised on-site lab setting. Optimal configurations will be used. The storage phase configuration will be used until the time for voiding/catheterization. The training procedure will be repeated for up to 8 hours daily on-site until three consecutive stable days of maintaining a consistent capacity values are achieved and deemed safe. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation (urodynamics and questionnaires). On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home-based training for bladder capacity.
Study NCT04879862 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epidural stimulation + Bladder Voiding Efficiency Training
Description: We will conduct training for voiding efficiency in a supervised on-site lab setting while the participant continues his/her training for capacity. Voiding without catheterization will be attempted. The training procedure will be repeated for up to 8 hours on-site until three stable days of maintaining a consistent voiding efficiency are achieved and deemed safe. The participant will be sent home for one day to perform the stimulation at home. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation and questionnaires. On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home program integrating bladder training for capacity and voiding
Study NCT04880304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer Heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
Study NCT05584930 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood sample
Description: * Visit 1 : At inclusion (day 1 of chemotherapy treatment)~* Visit 2 : Onset of aplasia~* Visit 3a : day 1 of the 1st febrile aplasia~* Visit 3b : day 3 of the 1st febrile episode~* Visit 3c : day 8 of the 1st febrile episode~* Visit 4a : second febrile episode (after 7 days)~* Visit 4b : day 3 of the second febrile episode (after 7 days)
Study NCT06286527 — intervention group
Intervention type: OTHER
Intervention: anonymous self-administered online questionnaire
Description: proposition to participate through billboards with a QR code leading to the questionnaire.
Study NCT05162417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 1mg/ml of Methylene as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
Study NCT05162417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toluidine Blue O
Description: 1mg/ml of Toluidine blue o as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
Study NCT04939233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton glove
Description: A robotic hand orthosis (exoskeleton glove) will have been developed that is able to naturalistically bend the finger joints of the individuals based on intuitive voice commands
Study NCT05003089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Tablet, oral.
Study NCT05003089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1830839
Description: Tablet, oral.
Study NCT05003089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Tablet, oral.
Study NCT05003089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral.
Study NCT05131048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: this group will perform conventional therapy
Study NCT05131048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: this group will perform home based exercises
Study NCT05524168 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT for metastatic lesions
Study NCT05524168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.
Study NCT05524168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.
Study NCT05524168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.
Study NCT04928950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
Study NCT04747977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-DED
Description: 0.2mg dexamethasone ophthalmic insert
Study NCT04747977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-DED
Description: 0.3mg dexamethasone ophthalmic insert
Study NCT04747977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OTX-DED
Description: Hydrogel vehicle ophthalmic insert
Study NCT05172765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation Device
Description: Low-level, electrical stimulation of the outer ear (LLTS), using a transcutaneous electrical nerve stimulation (TENS) device.
Study NCT05172765 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation Device
Description: Low-level, electrical stimulation of the outer ear (LLTS), using a transcutaneous electrical nerve stimulation (TENS) device.
Study NCT04838743 — intervention group
Intervention type: DRUG
Intervention: IDegLira
Description: Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study.
Study NCT05187676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen saturation measurement using the IPAM device
Description: Skin oxygen saturation rate will be measured (%) using the non-contact optical device under evaluation called IPAM
Study NCT05187676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 device
Description: Skin TcPO2 will be measured (mmHg) using the reference device called PeriFlux6000
Study NCT06574581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSC01
Description: The initial 3 subjects will receive low-dose AD-MSC (1x10E6 cells/kg) infusion therapy only once; if no adverse events after 4 weeks, the next 4-7 subjects will receive medium-dose AD-MSC (1x10E6 cells/kg) infusion therapy twice; if no adverse events after 4 weeks of the last infusion, the next 8-10 subjects will receive high-dose AD-MSC (1x10E6 cells/kg) infusion therapy three times.
Study NCT05463380 — intervention group
Intervention type: OTHER
Intervention: standard of care
Description: The patient will be treated following the satndard of care in the participating units
Study NCT05251337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Participants will receive Wyndmere Naturals, Inc. aromatherapy patches. The hydrogel adhesive patches are infused with essential oil for inhaled aromatherapy treatment. The aromatherapy patches provide an occlusive barrier that is hypoallergenic, allowing essential oils to be inhaled without coming in direct contact with the skin. Participants indicating nausea/vomiting is their symptom of concern will receive peppermint aromatherapy patches (or mandarin if peppermint sensitivity). Participants indicating anxiety is their symptom of concern will receive lavender aromatherapy patches.
Study NCT05251337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).
Study NCT05988177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrimycin tablets
Description: Carrimycin tablets are administered 400mg a day orally for 7 days.
Study NCT06247878 — intervention group
Intervention type: DEVICE
Intervention: Skiin underwear chest band
Description: Participants will be asked to wear a skiin underwear chest band during a polysomnography test.
Study NCT05952583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Additional ultrasound measurements during pregnancy
Study NCT05715294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Application
Description: A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
Study NCT05315193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured In-patient and Home plan
Description: A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
Study NCT05315193 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Therapy
Description: In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)
Study NCT05737810 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT05234684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib + R-CHOP
Description: The orelabrutinib is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
Study NCT05234684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + R-CHOP
Description: The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
Study NCT02004782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
Study NCT02004782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
Study NCT06387901 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel Chemotherapy
Description: Participants will receive paclitaxel, a taxane chemotherapeutic agent used in the treatment of breast cancer. The administration involves an intravenous infusion of paclitaxel at a dosage of 80 mg/m². The treatment is scheduled once a week, continuing for a total duration of 12 weeks. This regimen is part of a (neo-)adjuvant therapy for female patients diagnosed with stage II or III breast cancer. The intervention aims to assess the pharmacokinetics of paclitaxel in relation to patient body composition and physical activity, evaluating its impact on dose-limiting toxicities and overall treatment efficacy.
Study NCT05131100 — intervention group
Intervention type: DRUG
Intervention: Somavert
Description: As provided in real world practice
Study NCT06077227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality therapy
Description: 6 2 times weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys
Study NCT06077227 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: matched control group
Description: taking the same surveys as the VR intervention group on a weekly basis for 6 weeks
Study NCT06073574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: MRI Scans as specified in the corresponding arm group.
Study NCT05471661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent-specific T cells (penta-STs)
Description: Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
Study NCT05033067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3BC
Description: The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
Study NCT05198830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05198830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05198830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05198830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT05198830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and FDG-PET/CT
Study NCT05198830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT and FDG-PET/CT
Study NCT05198830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT05198830 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT05198830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET/CT
Study NCT05198830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET/CT
Study NCT05198830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05198830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05198830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine
Description: Given PO
Study NCT05198830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT05198830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV
Study NCT05198830 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo thoracic radiation
Study NCT05198830 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo thoracic radiation
Study NCT06127667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: use of single bout of aerobic exercise
Study NCT04039672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: 5mm skin metastasis or primary melanoma biopsy
Study NCT06079398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navepegritide
Description: Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
Study NCT06079398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Navepegritide
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
Study NCT06319170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Extended Release
Description: Powder and vehicle for injectable suspension
Study NCT06319170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: IntraMuscular Injection